Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis - Scorecard - MDSpire

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.

  • By

  • March 4, 2026

  • 2 min

Share

Clinical Scorecard: Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

At a Glance

CategoryDetail
ConditionRelapsing Multiple Sclerosis
Key MechanismsObservational registry to track outcomes, safety, and patient experience with BRUMVI.
Target PopulationPatients with confirmed multiple sclerosis starting BRUMVI.
Care SettingReal-world clinical practice.

Key Highlights

  • Observational registry collecting real-world data on BRUMVI.
  • Focus on outcomes, safety, and patient experience over 192 weeks.
  • Eligibility includes confirmed MS diagnosis and no prior BRUMVI infusions.

Guideline-Based Recommendations

Diagnosis

  • Confirmed diagnosis of multiple sclerosis.

Management

  • Patients should be prescribed BRUMVI and not have received prior infusions.

Monitoring & Follow-up

  • Participants complete health questionnaires and brief assessments.

Risks

  • Exclusion for recent live vaccines and active infections.

Patient & Prescribing Data

Patients with relapsing multiple sclerosis starting BRUMVI.

Registry aims to gather data on the efficacy and safety of BRUMVI in everyday practice.

Clinical Best Practices

  • Continue usual clinical care while participating in the registry.
  • Ensure eligibility criteria are met before referral.

References

Original Source(s)

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

  • by

  • March 4, 2026

Related Content

Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations